S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
$0.99
N/A0.25N/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$0.21
$0.31
$0.19
$3.35
$2.18M2.67380,570 shs133,953 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$5.44
+2.3%
$4.45
$2.31
$7.15
$28.28M1.05152,396 shs21,347 shs
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
$14.68
$14.68
$11.53
$15.89
$213.33M1.43119,209 shs113,575 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.95
-6.7%
$1.84
$1.55
$3.14
$7.63M0.9218,140 shs30,941 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
+0.24%-14.58%-40.75%-73.71%-88.42%
Lipocine Inc. stock logo
LPCN
Lipocine
+2.26%-15.13%+27.70%+44.30%+4.92%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
0.00%-0.34%-0.07%+11.21%+18.39%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-6.70%-7.14%+20.37%+10.17%-37.10%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.9391 of 5 stars
3.53.00.00.00.00.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
3.00
Buy$10.00412.82% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A($0.71) per shareN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$500K57.88N/AN/A$3.83 per share1.42
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.30M0.98N/AN/A$4.93 per share0.40

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$18.85M-$5.66N/AN/AN/A-603.40%-421.35%5/20/2024 (Estimated)
Lipocine Inc. stock logo
LPCN
Lipocine
-$16.35M-$3.05N/AN/AN/A-63.28%-58.27%5/9/2024 (Estimated)
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-$1.18M-$0.08N/AN/AN/A-6.24%-6.09%5/2/2024 (Estimated)
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$14.12M-$3.86N/AN/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)

Latest MACK, LPCN, ADDXF, CNSP, and PULM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.57-$0.57-$0.57N/A$2.20 million
3/7/2024Q4 2023
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.53-$0.42+$0.11-$0.42N/A$0.22 million
3/7/2024Q4 2023
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A-$0.01-$0.01-$0.01N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
0.26
0.26
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
8.69
8.69
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A
43.50
43.50
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
5.33
5.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
63.97%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
26N/AN/ANot Optionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
310.64 million10.22 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
175.32 million5.05 millionNo Data
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
42614.53 million10.34 millionOptionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
283.65 million3.52 millionNot Optionable

MACK, LPCN, ADDXF, CNSP, and PULM Headlines

SourceHeadline
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comPulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - April 16 at 2:22 AM
Cipla Share PriceCipla Share Price
business-standard.com - March 29 at 7:49 AM
PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 28 at 11:31 PM
Pulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdatePulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 28 at 11:46 AM
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdatePulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
prnewswire.com - March 28 at 9:05 AM
Cipla Ltd CIPLACipla Ltd CIPLA
morningstar.com - February 15 at 11:00 PM
Global deaths from fungal disease have doubled in a decade – new studyGlobal deaths from fungal disease have doubled in a decade – new study
theconversation.com - January 13 at 7:42 AM
Five things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headliners
bizjournals.com - January 10 at 7:51 AM
Pulmatrix shuts down study, explores salePulmatrix shuts down study, explores sale
bizjournals.com - January 9 at 3:43 PM
Pulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The StudyPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Study
nasdaq.com - January 8 at 1:11 PM
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic AlternativesPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
marketwatch.com - January 8 at 1:11 PM
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
finance.yahoo.com - January 8 at 1:11 PM
Stocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata SteelStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steel
msn.com - January 8 at 12:42 AM
Stock Market Today: Dr Reddys, Titan, And Reliance Power Shares In FocusStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focus
msn.com - January 8 at 12:42 AM
Trade Setup for Jan 8: IT earnings to be the Nifty 50s focal point this weekTrade Setup for Jan 8: IT earnings to be the Nifty 50's focal point this week
cnbctv18.com - January 7 at 9:11 AM
Pulmatrix Inc PULMPulmatrix Inc PULM
morningstar.com - November 12 at 9:08 AM
Pulmatrix Down on Q3 ResultsPulmatrix Down on Q3 Results
baystreet.ca - November 9 at 1:38 PM
Pulmatrix GAAP EPS of -$1.03, revenue of $1.75MPulmatrix GAAP EPS of -$1.03, revenue of $1.75M
msn.com - November 9 at 1:38 PM
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 1:38 PM
Aspergillosis Treatment Research Report 2023Aspergillosis Treatment Research Report 2023
finance.yahoo.com - October 23 at 3:27 PM
Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100
markets.businessinsider.com - September 19 at 9:49 AM
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigrainePulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
finance.yahoo.com - September 19 at 9:49 AM
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Heres Why You Should Buy the Stock NowPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
msn.com - September 11 at 3:15 PM
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazolePulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
finance.yahoo.com - August 23 at 6:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Addex Therapeutics logo

Addex Therapeutics

OTCMKTS:ADDXF
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
CNS Pharmaceuticals logo

CNS Pharmaceuticals

NASDAQ:CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Lipocine logo

Lipocine

NASDAQ:LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Merrimack Pharmaceuticals logo

Merrimack Pharmaceuticals

NASDAQ:MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Pulmatrix logo

Pulmatrix

NASDAQ:PULM
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.